Analysts expect Phibro Animal Health Corp (NASDAQ:PAHC) to post earnings of $0.43 per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Phibro Animal Health’s earnings, with the lowest EPS estimate coming in at $0.41 and the highest estimate coming in at $0.44. Phibro Animal Health reported earnings of $0.38 per share during the same quarter last year, which indicates a positive year over year growth rate of 13.2%. The firm is expected to issue its next quarterly earnings report on Monday, November 5th.

According to Zacks, analysts expect that Phibro Animal Health will report full year earnings of $1.80 per share for the current financial year, with EPS estimates ranging from $1.75 to $1.87. For the next fiscal year, analysts anticipate that the company will report earnings of $1.89 per share, with EPS estimates ranging from $1.88 to $1.90. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Phibro Animal Health.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Monday, August 27th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Phibro Animal Health had a return on equity of 39.81% and a net margin of 7.90%. The company had revenue of $211.80 million for the quarter, compared to the consensus estimate of $209.27 million. During the same quarter in the previous year, the business earned $0.39 EPS. Phibro Animal Health’s revenue was up 8.7% compared to the same quarter last year.

A number of research analysts recently issued reports on PAHC shares. BidaskClub upgraded Phibro Animal Health from a “hold” rating to a “buy” rating in a report on Thursday, June 21st. Barclays boosted their price target on Phibro Animal Health from $31.00 to $33.00 and gave the company an “underweight” rating in a report on Thursday, July 5th. Morgan Stanley boosted their price target on Phibro Animal Health from $36.00 to $46.00 and gave the company an “underweight” rating in a report on Wednesday, August 29th. Finally, Zacks Investment Research downgraded Phibro Animal Health from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $43.20.

In other Phibro Animal Health news, major shareholder Bfi Co., Llc sold 9,470 shares of the company’s stock in a transaction that occurred on Tuesday, July 17th. The stock was sold at an average price of $48.20, for a total transaction of $456,454.00. Following the transaction, the insider now owns 47,470 shares in the company, valued at approximately $2,288,054. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jack Bendheim sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $50.66, for a total value of $506,600.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at approximately $405,280. The disclosure for this sale can be found here. Insiders have sold a total of 343,960 shares of company stock worth $16,571,627 in the last quarter. Company insiders own 51.88% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in shares of Phibro Animal Health by 2,104.6% during the 1st quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock worth $151,000 after acquiring an additional 3,641 shares during the period. Meeder Asset Management Inc. boosted its position in shares of Phibro Animal Health by 149.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock worth $206,000 after purchasing an additional 2,676 shares in the last quarter. Piedmont Investment Advisors LLC bought a new stake in shares of Phibro Animal Health in the 2nd quarter worth approximately $213,000. Janus Henderson Group PLC bought a new stake in shares of Phibro Animal Health in the 2nd quarter worth approximately $222,000. Finally, Highbridge Capital Management LLC bought a new stake in shares of Phibro Animal Health in the 1st quarter worth approximately $214,000. Hedge funds and other institutional investors own 49.20% of the company’s stock.

Shares of NASDAQ:PAHC opened at $42.30 on Thursday. Phibro Animal Health has a 1 year low of $32.05 and a 1 year high of $54.62. The stock has a market cap of $1.71 billion, a P/E ratio of 24.31, a price-to-earnings-growth ratio of 2.44 and a beta of 0.89. The company has a current ratio of 2.90, a quick ratio of 1.66 and a debt-to-equity ratio of 1.62.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 26th. Shareholders of record on Wednesday, September 5th will be issued a dividend of $0.10 per share. The ex-dividend date of this dividend is Tuesday, September 4th. This represents a $0.40 dividend on an annualized basis and a dividend yield of 0.95%. Phibro Animal Health’s dividend payout ratio (DPR) is 22.99%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

Featured Article: Understanding Relative Strength Index

Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.